Leviticus Partners holds 235,000 Harvard Bioscience common shares, representing a 5.2% stake. The position is classified as passive because the securities were acquired in the ordinary course and not to change or influence Harvard Bioscience’s control, a distinction relevant to investors assessing ownership intent.
Key Highlights
- Leviticus Partners’ reported position represents 5.2% of Harvard Bioscience.
- The disclosed holding covers 235,000 common shares.
- The securities were described as acquired in the ordinary course without a control-changing purpose.
Harvard Bioscience Inc (NASDAQ: HBIO) has a 5.2% ownership position held by Leviticus Partners LP. The reported interest covers 235,000 common shares.
Passive 5.2% Ownership Position
Leviticus Partners LP used a Schedule 13G/A to report the holding. The record identifies the security as common stock and dates the position September 14, 2026. The reported position is shown as 235,000 shares with 5.2% beneficial ownership. The ownership record also lists 235,000 shares over which Leviticus Partners LP has voting power and 235,000 shares over which it has dispositive power. Harvard Bioscience’s listed address is 84 October Hill Road, Holliston, Massachusetts 01746. Adam M Hutt is named as managing member of Leviticus Partners LP, and the record is dated September 22, 2026. The certification states that the securities were acquired and held in the ordinary course of business. It also states that the position was not acquired or held to change or influence Harvard Bioscience’s control, except for activities solely connected with a nomination under Section 240.14a-11.
FAQs
Q: How many Harvard Bioscience shares does Leviticus Partners own?
A: Leviticus Partners LP reports beneficial ownership of 235,000 Harvard Bioscience common shares. The position equals 5.2% ownership.
Q: Is Leviticus Partners’ Harvard Bioscience stake an activist investment?
A: No, Leviticus Partners’ Harvard Bioscience stake is described as a passive ownership position. The certification states it was not acquired or held to change or influence Harvard Bioscience’s control, except for activities solely connected with a nomination under Section 240.14a-11.
Q: Who is identified in the Harvard Bioscience ownership record?
A: Leviticus Partners LP is identified as the reporting holder in the Harvard Bioscience ownership record. Adam M Hutt is identified as its managing member.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.